Nazimuddin CHISHTI, Mohamed Hassan DEHGHAN

Nano-embedded microparticles based dry powder inhaler for lung cancer treatment

Lower efficacy of chemotherapeutic agents through the systemic route for treatment of lung cancer isattributed to its lower concentration in the lungs. Conversely, higher concentrations of drug in the lungs can beachieved by pulmonary administration via the inhalation route. For effective deposition of the formulation at thetarget region (small airways and alveoli) of the lung, the aerodynamic diameter has to be controlled (1-5 µm) and itsretention is of key importance. The present study attempted to design a dry powder inhalation formulation withcombined benefits of micron- and nano-sized particles [nano-embedded microparticles (NEMs)], which uponredispersion, results in nanoparticles (NPs) exhibiting good retention in the lungs. The present attempt is the foremostone to utilize NEMs administered by pulmonary route for the treatment of lung cancer. Docetaxel (DTX) NPs wasformulated using sonication solvent evaporation technique and characterized. Thereafter, DTX-NPs were embeddedinto microparticles using the spray drying technique. The NEMs exhibited the desired flow properties with Carr’sindex 10.18±2.79 and Hausner ratio 1.11±0.034. The mass median aerodynamic diameter was 3.74±0.11 µm and thefine particle fraction 42.96±1.66%. Redispersed NP fraction was 47.78±4.65% with NPs retaining the desiredproperties. NPs demonstrated a sustained release of upto 144 h. The particle size and PDI of the redispersed NPs wereunaffected. NEMs displayed stability upon charging under accelerated conditions for upto 3 months. Comparison ofthe cytotoxicity of DTX and DTX-NEMs revealed that the DTX-NEMs had more cytoxicity owing to the increaseduptake of liberated NPs by cells. The prepared formulation could successfully entrap NPs (with mucus barrierevading properties) in lactose microparticles, which can be deposited in the lungs and eventually, disintegrate to giveback NPs under simulated lung conditions. The results suggest that the developed NEMs can be used in inhaledchemotherapy for the treatment of non-small cell lung cancer.

PDF

___

[1] Kaminskas LM, McLeod VM, Ryan GM, Kelly BD, Haynes JM, Williamson M, et al. Pulmonary administration of a doxorubicin-conjugated dendrimer enhances drug exposure to lung metastases and improves cancer therapy. J Control Release Off J Control Release Soc. 2014; 183: 18–26. [CrossRef]
[2] Bakhtiary Z, Barar J, Aghanejad A, Saei AA, Nemati E, Ezzati Nazhad Dolatabadi J, et al. Microparticles containing erlotinib-loaded solid lipid nanoparticles for treatment of non-small cell lung cancer. Drug DevInd Pharm. 2017; 43(8): 1244–1253. [CrossRef]
[3] Pallagi E, Karimi K, Ambrus R, Szabo-Revesz P, Csoka I. New aspects of developing a dry powder inhalation formulation applying the quality-by-design approach. Int J Pharm. 2016; 511(1):151–160. [CrossRef]
[4] Bhardwaj A, Mehta S, Yadav S, Singh SK, Grobler A, Goyal AK, et al. Pulmonary delivery of antitubercular drugs using spray-dried lipid-polymer hybrid nanoparticles. Artificial Cells Nanomedicine Biotechnology. 2016; 44(6): 1544–1555. [CrossRef]
[5] Lee WH, Loo CY, Traini D, Young PM. Inhalation of nanoparticle-based drug for lung cancer treatment: Advantages and challenges.Spec Issue Inhal. 2015; 10(6): 481–489. [CrossRef]
[6] Zarogoulidis P, Chatzaki E, Porpodis K, Domvri K, Hohenforst-Schmidt W, Goldberg EP, et al. Inhaled chemotherapy in lung cancer: future concept of nanomedicine. Int J Nanomedicine. 2012; 7: 1551–1572. [CrossRef]
[7] Beck Broichsitter M, Kleimann P, Schmehl T, Betz T, Bakowsky U, Kissel T, et al. Impact of lyoprotectants for the stabilization of biodegradable nanoparticles on the performance of air-jet, ultrasonic, and vibrating-mesh nebulizers. Eur J Pharm Biopharm Off J Arbeitsgemeinschaft Pharm Verfahrenstechnik EV. 2012; 82(2): 272–280. [CrossRef]
[8] Azarmi S, Tao X, Chen H, Wang Z, Finlay WH, Lobenberg R, et al. Formulation and cytotoxicity of doxorubicin nanoparticles carried by dry powder aerosol particles. Int J Pharm. 2006; 319(1–2): 155–161. [CrossRef]
[9] Roa WH, Azarmi S, Al-Hallak MHDK, Finlay WH, Magliocco AM, Lobenberg R. Inhalable nanoparticles, a noninvasive approach to treat lung cancer in a mouse model. J Control Release Off J Control Release Soc. 2011; 150(1): 49–55. [CrossRef]
[10] Tian J, Min Y, Rodgers Z, Wan X, Qiu H, Mi Y, et al. Nanoparticle delivery of chemotherapy combination regimen improves the therapeutic efficacy in mouse models of lung cancer. Nanomedicine Nanotechnol Biol Med. 2017; 13(3): 1301–1307. [CrossRef]
[11] Patel AR, Chougule MB, I T, Patlolla R, Wang G, Singh M. Efficacy of aerosolized celecoxib encapsulated nanostructured lipid carrier in non-small cell lung cancer in combination with docetaxel. Pharm Res. 2013; 30(5): 1435–1446. [CrossRef]
[12] Chen R, Xu L, Fan Q, Li M, Wang J, Wu L, et al. Hierarchical pulmonary target nanoparticles via inhaled administration for anticancer drug delivery. Drug Deliv. 2017; 24(1): 1191–1203. [CrossRef]
[13] Choi SH, Byeon HJ, Choi JS, Thao L, Kim I, Lee ES, et al. Inhalable self-assembled albumin nanoparticles for treating drug-resistant lung cancer. J Control Release Off J Control Release Soc. 2015; 197: 199–207. [CrossRef]
[14] Varshosaz J, Taymouri S, Hamishehkar H, Vatankhah R, Yaghubi S. Development of dry powder inhaler containing tadalafil-loaded PLGA nanoparticles. Res Pharm Sci. 2017; 12(3): 222–232. [CrossRef]
[15] Ryan GM, Kaminskas LM, Kelly BD, Owen DJ, McIntosh MP, Porter CJH. Pulmonary administration of PEGylatedpolylysine dendrimers: absorption from the lung versus retention within the lung is highly sizedependent. Mol Pharm. 2013; 10(8): 2986–2995. [CrossRef]
[16] Kuzmov A, Minko T. Nanotechnology approaches for inhalation treatment of lung diseases. J Control Release Off J Control Release Soc. 2015; 219: 500–518. [CrossRef]
[17] Yang Y, Cheow WS, Hadinoto K. Dry powder inhaler formulation of lipid-polymer hybrid nanoparticles via electrostatically-driven nanoparticle assembly onto microscale carrier particles. Int J Pharm. 2012; 434(1–2): 49–58. [CrossRef]
[18] Ogain ON, Li J, Tajber L, Corrigan OI, Healy AM. Particle engineering of materials for oral inhalation by dry powder inhalers. I-Particles of sugar excipients (trehalose and raffinose) for protein delivery. Int J Pharm. 2011 Feb 28; 405(1–2): 23–35. [CrossRef]
[19] Maury M, Murphy K, Kumar S, Shi L, Lee G. Effects of process variables on the powder yield of spray-dried trehalose on a laboratory spray-dryer. Eur J Pharm Biopharm Off J Arbeitsgemeinschaft Pharm Verfahrenstechnik EV. 2005; 59(3): 565–573. [CrossRef]
[20] Torge A, Grutzmacher P, Mucklich F, Schneider M. The influence of mannitol on morphology and disintegration of spray-dried nano-embedded microparticles. Eur J Pharm Sci Off J Eur Fed Pharm Sci. 2017; 104: 171–179. [CrossRef]
[21] Ungaro F, d’Angelo I, Coletta C, d’Emmanuele di Villa Bianca R, Sorrentino R, Perfetto B, et al. Dry powders based on PLGA nanoparticles for pulmonary delivery of antibiotics: modulation of encapsulation efficiency, release rate and lung deposition pattern by hydrophilic polymers. J Control Release Off J Control Release Soc. 2012; 157(1): 149– 159. [CrossRef]
[22] Muralidharan P, Malapit M, Mallory E, Hayes DJ, Mansour HM. Inhalable nanoparticulate powders for respiratory delivery. Nanomedicine Nanotechnol Biol Med. 2015; 11(5): 1189–1199. [CrossRef][23] Pilcer G, Amighi K. Formulation strategy and use of excipients in pulmonary drug delivery. Int J Pharm. 2010; 392(1–2): 1–19. [CrossRef]
[24] Ungaro F, d’Angelo I, Miro A, La Rotonda MI, Quaglia F. Engineered PLGA nano- and micro-carriers for pulmonary delivery: challenges and promises. J Pharm Pharmacol. 2012; 64(9): 1217–1235. [CrossRef]
[25] Chishti N, Jagwani S, Dhamecha D, Jalalpure S, Dehghan MH. Preparation, Optimization, and In Vivo Evaluation of Nanoparticle-Based Formulation for Pulmonary Delivery of Anticancer Drug. Med Kaunas Lith. 2019; 55(6): 294. [CrossRef]
[26] Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumorselective macromolecular drug targeting. Adv Enzyme Regul. 2001; 41: 189–207. [CrossRef]
[27] Zhang J, Wu L, Chan H-K, Watanabe W. Formation, characterization, and fate of inhaled drug nanoparticles. Adv Drug Deliv Rev. 2011; 63(6): 441–455. [CrossRef]
[28] Godugu C, Patel AR, Doddapaneni R, Marepally S, Jackson T, Singh M. Inhalation delivery of Telmisartan enhances intratumoral distribution of nanoparticles in lung cancer models. J Control Release Off J Control Release Soc. 2013; 172(1): 86–95. [CrossRef]
[29] Jain D, Athawale R, Bajaj A, Shrikhande S, Goel PN, Gude RP. Studies on stabilization mechanism and stealth effect of poloxamer 188 onto PLGA nanoparticles. Colloids Surf B Biointerfaces. 2013; 109: 59–67. [CrossRef]
[30] Broadhead J, Rouan SK, Hau I, Rhodes CT. The effect of process and formulation variables on the properties of spray-dried beta-galactosidase. J Pharm Pharmacol. 1994; 46(6): 458–467. [CrossRef]